Insulinlike growth factor (IGF) I and IGF-II are synthesized in osteoblasts and stimulate proliferation, differentiation, and matrix synthesis in these cells. There is some evidence that IGFs act on bone cells not only by paracrine but also by endocrine pathways, suggesting that circulating IGFs may be of importance for the regulation of bone metabolism. On the other hand, the serum IGF-I level is also thought to be a good indicator of the nutritional conditions in hemodialysis patients. The present study was performed to analyze the correlations of circulating levels of IGF-I, IGF-II, IGF-binding protein (IGFBP) 1 and IGFBP-3 with biochemical markers of bone metabolism and parameters of the urea kinetic model which reflect nutritional conditions in hemodialysis patients. We also examined the differences between these relationships in male and female patients on hemodialysis. Sixty-two hemodialysis patients, 36 men (male group) and 26 women (female group), were included in this study. We measured the serum levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. The bone mineral content (BMC) of the radius was measured by dual-energy X-ray absorptiometry. We calculated Kt/V, protein catabolic rate, and percent creatinine generation rate (%CGR). We also examined the relationships between serum levels of IGFs and BMC and the parameters of the urea kinetic model. It was found that the serum levels of IGF-I in the hemodialysis patients were almost the same as those in the control group. However, the serum levels of IGF-II, IGFBP-1, and IGFBP-3 in the hemodialysis patients were significantly higher than those in the control group. In the male group, the serum IGF-I levels showed a significant correlation with both serum intact parathyroid hormone levels and BMC, but no significant correlations between these indices were found in the female group. The serum levels of both IGF-I and IGF-II showed significant correlations with %CGR in the male group, but not in the female group. Stepwise multiple regression analysis was performed to clarify the relationship between serum levels of IGFs and BMC or %CGR. It was found that age, hemodialysis duration, serum intact parathyroid hormone levels, and sex were independent factors associated with BMC. The %CGR was associated independently with serum levels of IGF-I, and IGF-II and with the presence of diabetes mellitus. In conclusion, it is thought that serum levels of IGF-I and IGF-II can be used as indices of nutritional conditions in hemodialysis patients. However, the serum IGF-I level cannot be used as a marker of bone metabolism in hemodialysis patients.

1.
Ota S, Takahashi K, Taniai K, Makino H: Bone metabolism and daily physical activity in women undergoing hemodialysis. Nippon Jinzo Gakkai Shi 1997;39:441–446.
2.
Weinreich T, Zapf J, Schmidt-Gayk H, Ritzel H, Delling G, Reichel H: Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease. Clin Nephrol 1999;51:27–33.
3.
Shimid C: IGFs: Function and clinical importance. 2. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med 1993;234:535–542.
4.
Grispoon SK, Baum HBA, Peterson S, Klibanski A: Effects of rh-IGH-I administration on bone turnover during short-term fasting. J Clin Invest 1995;96:900–906.
5.
Hirschberg R, Adler S: Insulin-like growth factor system and the kidney: Physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis 1998;31:901–919.
6.
Andress DL, Pandian MR, Endres DB, Kopp JP: Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int 1989;36:471–477.
7.
Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K: Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997;12:1272–1279.
8.
Sanaka T, Shinobe M, Ando M, Hizuka N, Kawaguchi H, Nihei H: IGF-I as an early indicator of malnutrition in patients with end-stage renal disease. Nephron 1994;67:73–81.
9.
Numata M, Yamamoto H, Kawaguchi Y, Osaka N, Nakayama M, Kubo H, Shigematsu T, Hosoya T: A study of association between lean body mass and serum insulin-like growth factor-1 in continuous ambulatory peritoneal dialysis. Nippon Jinzo Gakkai Shi 1999;41:8–13.
10.
Jacob V, Carpentier JEL, Salzano S, Naylor V, Wild G, Brown CB, Nahas AME: IGF-1, a marker of undernutrition in hemodialysis patients. Am J Clin Nutr 1990;52:39–44.
11.
Himmelfarb J, Holbrook D, McMonagle E, Robinson R, Nye L, Spratt D: Kt/V, nutritional parameters, serum cortisol, and insulin growth factor-1 levels and patient outcome in hemodialysis. Am J Kidney Dis 1994;24:473–479.
12.
Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125–137.
13.
Shinobe M, Sanaka T, Nihei H, Sugino N: IGF-I/IGFBP-1 as an index for discrimination between responder and nonresponder to recombinant human growth hormone in malnourished uremic patients on hemodialysis. Nephron 1997;77:29–36.
14.
Gotch FA, Sargent JA: A mechanistic analysis of National Cooperative Dialysis Study. Kidney Int 1985;28:526–534.
15.
Shinzato T, Nakai S, Fujita Y, Takai I, Morita H, Nakane K, Maeda K: Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994;67:280–290.
16.
Nakai S, Shinzato T, Miwa M, Iwayama N, Matsumoto Y, Takai I, Wakai K, Maeda K: Predialysis serum albumin concentration of creatinine generation rate do not reflect the same pathophysiologic status. Clin Exp Nephrol 1998;2:44–49.
17.
Tsukamoto Y, Moriya R, Nagaba Y, Morishita T, Izumida I, Okubo M: Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. Am J Kidney Dis 1995;25:879–886.
18.
Koiwa F, Ideura T: Detection of radial bone mineral loss by computed X-ray densitometry in regular hemodialysis (HD) patients (in Japanese). J Jpn Dial Ther Soc 1999;32:167–173.
19.
Daughaday WH, Trivedi B: Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: Description of a free E domain peptide in serum. J Clin Endocrinol Metab 1992;75:641–645.
20.
Fouque D, Peng SC, Kopple JD: Pharmacokinetics of recombinant human insulin-like growth factor-1 in dialysis patients. Kidney Int 1995;47:869–875.
21.
Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(suppl 1):11–19.
22.
Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, Malaspina M, Fiorini F, Mituto F, Tizianello A: Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997:99:97–105.
23.
Kuwahara M, Akiba T, Kurihara S, Takeuchi M, Sakurai Y, Suga M, Yoneshima H, Marumo F: The effect of menopause on bone in female hemodialyzed patients (in Japanese). J Jpn Dial Ther Soc 1995;28:879–884.
24.
Lowrie EG, Lew NL, Huang WH: Race and diabetes as death risk predictors in hemodialysis patients. Kidney Int 1992;42(suppl 38):22–31.
25.
Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan (as of Dec. 31, 1994) (in Japanese). J Jpn Dial Ther Soc 1996;29:1–22.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.